Company intelligence / Profile preview

MapLight Therapeutics

Palo Alto / Burlington*, California / Massachusetts*, United Statesmaplightrx.com ↗

Ownership: Public · MPLT
Employees: ~55
Development stage: Phase 2

Overview

MapLight has advanced a robust pipeline with two product candidates in the clinic. Lead candidate ML‑007C‑MA (a muscarinic agonist) entered Phase 2 trials for schizophrenia and Alzheimer’s disease psychosis in 2024. The company leverages a circuit-based approach to develop targeted therapies for CNS disorders with significant unmet need. Clinical data from similar mechanisms suggest strong efficacy with improved side effect profiles compared to traditional antipsychotics

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

7 assets

ML-007/PAC

6 more assets in the full pipeline.

Request access →

Financials

Market cap: $581.8M
Total revenue: $0
Enterprise value: $279.1M

Beyond the preview

Go deeper on MapLight Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MapLight Therapeutics.

Explore the full profile